Target intelligence / Profile preview

Resistant dextrin (RD)

Target
RD
Molecular classification
Carbohydrate, Polysaccharide, Soluble dietary fiber, Prebiotic
01

Overview

Resistant dextrin is a soluble dietary fiber and prebiotic produced through the controlled heat and enzymatic treatment of starches, such as corn or wheat. Unlike standard maltodextrins, its unique glycosidic linkages allow it to resist enzymatic hydrolysis in the human small intestine, enabling the majority of the molecule to reach the large intestine intact. Once in the colon, it is fermented by commensal gut microbiota into short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate. These SCFAs act as signaling molecules that trigger the release of metabolic hormones like glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) through the activation of G-protein coupled receptors FFAR2 and FFAR3. Consequently, resistant dextrin plays a significant role in improving glucose homeostasis, enhancing satiety, and reducing visceral adiposity. Clinically, it is extensively investigated for its potential in managing type 2 diabetes, obesity, and metabolic syndrome.

Other names
Indigestible dextrinResistant maltodextrinSoluble corn fiberNutrioseFibersol-2
02

Mechanism of action

Resistant dextrin serves as a fermentable substrate for gut microbiota, producing short-chain fatty acids (SCFAs) that activate free fatty acid receptors (FFAR2/GPR43 and FFAR3/GPR41) on enteroendocrine L-cells to stimulate GLP-1 and PYY secretion. It also delays the absorption of dietary sugars in the small intestine and improves insulin signaling pathways in the liver and adipose tissue.

03

Biological functions

Prebiotic fermentationGut microbiota modulationShort-chain fatty acid productionIncretin (GLP-1/PYY) secretionSatiety regulationGlucose and lipid metabolism regulationGut barrier function maintenance
04

Disease associations

Type 2 Diabetes MellitusObesityMetabolic SyndromeDyslipidemiaConstipationSystemic inflammation
05

Safety considerations

Gastrointestinal distress (flatulence, bloating, abdominal distension)Osmotic diarrhea at high dosagesPotential interference with the absorption of certain oral medications
06

Interacting drugs

Metformin (often co-administered in metabolic studies)

1 more in the full profile.

07

Biomarkers

Hemoglobin A1c (HbA1c)Fasting blood glucose (FBG)Glucagon-like peptide-1 (GLP-1)Peptide YY (PYY)Short-chain fatty acids (SCFAs)Microbial diversity (e.g., Akkermansia, Prevotella abundance)

Beyond the preview

Go deeper on Resistant dextrin (RD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resistant dextrin (RD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call